MRT5429
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 20, 2025
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
(clinicaltrials.gov)
- P1/2 | N=910 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Influenza • Respiratory Diseases
June 26, 2024
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
(clinicaltrials.gov)
- P1/2 | N=1002 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases
April 12, 2024
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
(clinicaltrials.gov)
- P1/2 | N=1002 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company
New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases
1 to 3
Of
3
Go to page
1